Mental health problems and socioeconomic disadvantage: a controlled household study in rural Ethiopia.


Journal

International journal for equity in health
ISSN: 1475-9276
Titre abrégé: Int J Equity Health
Pays: England
ID NLM: 101147692

Informations de publication

Date de publication:
31 07 2019
Historique:
received: 12 10 2018
accepted: 21 07 2019
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 26 11 2019
Statut: epublish

Résumé

There is a lack of high quality population-based studies from low- and middle-income countries examining the relative economic status of households with and without a member with a mental health problem. The aim of the study was to explore the socio-economic status of households with a person with severe mental disorder (SMD; psychosis or bipolar disorder) or depression compared to households without an affected person. A population-based, comparative, cross-sectional household survey was conducted in Sodo district, south Ethiopia, between January and November 2015. Two samples were recruited, each with its own comparison group. Sample (1): households of 290 community-ascertained persons with a clinician-confirmed diagnosis of SMD and a comparison group of 289 households without a person with SMD. Sample (2): households of 128 people who attended the primary health care centre and who were identified by primary care staff as having a probable diagnosis of depressive disorder; and comparison households of 129 patients who attended for other reasons and who did not receive a diagnosis of depression. Household socioeconomic status (household income, consumption and asset-based wealth) was assessed using a contextualized version of theWorld Health Organization (WHO) Study on global Ageing and adult health (SAGE) questionnaire. Each disorder group (SMD and depression) was further divided into higher and lower disability groups on the basis of median score on the WHO Disability Assessment Schedule. Households of a person with SMD who had higher disability were more likely to have a poorer living standard (no toilet facility; p < 0.001). Having a reliable source of regular income was significantly lower in households of a person with SMD (p = 0.008) or depression (p = 0.046) with higher disability than the comparison group. Households of persons with SMD with higher disability earned less (p = 0.005) and owned significantly fewer assets (p < 0.001) than households without SMD. Households including persons with depression who had higher disability had lower income (p = 0.042) and reduced consumption (p = 0.048). Households with a member who had either SMD or depression were socioeconomically disadvantaged compared to the general population. Moreover, higher disability was associated with worse socio-economic disadvantage. Prospective studies are needed to determine the direction of association. This study indicates a need to consider households of people with SMD or depression as a vulnerable group requiring economic support alongside access to evidence-based mental healthcare.

Sections du résumé

BACKGROUND
There is a lack of high quality population-based studies from low- and middle-income countries examining the relative economic status of households with and without a member with a mental health problem. The aim of the study was to explore the socio-economic status of households with a person with severe mental disorder (SMD; psychosis or bipolar disorder) or depression compared to households without an affected person.
METHODS
A population-based, comparative, cross-sectional household survey was conducted in Sodo district, south Ethiopia, between January and November 2015. Two samples were recruited, each with its own comparison group. Sample (1): households of 290 community-ascertained persons with a clinician-confirmed diagnosis of SMD and a comparison group of 289 households without a person with SMD. Sample (2): households of 128 people who attended the primary health care centre and who were identified by primary care staff as having a probable diagnosis of depressive disorder; and comparison households of 129 patients who attended for other reasons and who did not receive a diagnosis of depression. Household socioeconomic status (household income, consumption and asset-based wealth) was assessed using a contextualized version of theWorld Health Organization (WHO) Study on global Ageing and adult health (SAGE) questionnaire. Each disorder group (SMD and depression) was further divided into higher and lower disability groups on the basis of median score on the WHO Disability Assessment Schedule.
RESULTS
Households of a person with SMD who had higher disability were more likely to have a poorer living standard (no toilet facility; p < 0.001). Having a reliable source of regular income was significantly lower in households of a person with SMD (p = 0.008) or depression (p = 0.046) with higher disability than the comparison group. Households of persons with SMD with higher disability earned less (p = 0.005) and owned significantly fewer assets (p < 0.001) than households without SMD. Households including persons with depression who had higher disability had lower income (p = 0.042) and reduced consumption (p = 0.048).
CONCLUSIONS
Households with a member who had either SMD or depression were socioeconomically disadvantaged compared to the general population. Moreover, higher disability was associated with worse socio-economic disadvantage. Prospective studies are needed to determine the direction of association. This study indicates a need to consider households of people with SMD or depression as a vulnerable group requiring economic support alongside access to evidence-based mental healthcare.

Identifiants

pubmed: 31366362
doi: 10.1186/s12939-019-1020-4
pii: 10.1186/s12939-019-1020-4
pmc: PMC6670213
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

121

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/M025470/1
Pays : United Kingdom
Organisme : Department of Health
ID : 16/136/54
Pays : United Kingdom

Références

Br J Psychiatry. 2006 Aug;189:109-17
pubmed: 16880479
Int J Methods Psychiatr Res. 2013 Jun;22(2):110-37
pubmed: 23657924
Compr Psychiatry. 2011 Jan-Feb;52(1):17-25
pubmed: 21220061
Epidemiol Psychiatr Sci. 2019 Aug;28(4):397-407
pubmed: 29143723
Acta Psychiatr Scand Suppl. 1999;397:11-7
pubmed: 10470349
J Affect Disord. 2012 Feb;136(3):340-9
pubmed: 22196052
Soc Sci Med. 2014 Apr;106:20-7
pubmed: 24524962
Int J Methods Psychiatr Res. 2003;12(1):3-21
pubmed: 12830306
BMC Med. 2015 Apr 10;13:79
pubmed: 25879831
Br J Psychiatry. 2006 Sep;189:241-6
pubmed: 16946359
J Affect Disord. 2015 Nov 1;186:32-9
pubmed: 26226431
Health Qual Life Outcomes. 2017 Apr 5;15(1):64
pubmed: 28381230
Am J Epidemiol. 2003 Jan 15;157(2):98-112
pubmed: 12522017
Am J Psychiatry. 2008 Jun;165(6):703-11
pubmed: 18463104
Bull World Health Organ. 2003;81(8):609-15
pubmed: 14576893
Health Serv Res. 2000 Dec;35(5 Pt 3):32-42
pubmed: 16148950
Br J Psychiatry. 2001 Mar;178:228-33
pubmed: 11230033
Psychiatry Res. 2013 Dec 15;210(2):653-61
pubmed: 23972787
Int J Soc Psychiatry. 2002 Sep;48(3):200-8
pubmed: 12413248
BMC Psychiatry. 2014 Jul 07;14:194
pubmed: 24999041
J Epidemiol Community Health. 2006 Jan;60(1):7-12
pubmed: 16361448
PLoS Med. 2012;9(12):e1001359
pubmed: 23300387
Br J Psychiatry. 2016 Jan;208 Suppl 56:s4-12
pubmed: 26447174
Int J Epidemiol. 2012 Jun;41(3):871-86
pubmed: 22438428
Psychol Med. 2008 Oct;38(10):1485-93
pubmed: 18184442
BMC Psychiatry. 2016 Sep 07;16(1):311
pubmed: 27604273
J Health Soc Behav. 2001 Sep;42(3):277-94
pubmed: 11668774
Br J Psychiatry. 2003 Aug;183:121-31
pubmed: 12893665
Trop Med Int Health. 2007 Jan;12(1):130-9
pubmed: 17207157
PLoS One. 2014 Feb 18;9(2):e88437
pubmed: 24558389
Soc Psychiatry Psychiatr Epidemiol. 2012 Mar;47(3):351-9
pubmed: 21293847
BMJ Open. 2015 Feb 23;5(2):e006355
pubmed: 25712818
Br J Psychiatry. 2010 Aug;197(2):114-21
pubmed: 20679263
Afr J Psychiatry (Johannesbg). 2008 Aug;11(3):191-8
pubmed: 19588042
Soc Psychiatry Psychiatr Epidemiol. 2013 May;48(5):845-51
pubmed: 23007296
World Psychiatry. 2005 Oct;4(3):181-5
pubmed: 16633546
Int Rev Psychiatry. 2003 Feb-May;15(1-2):91-6
pubmed: 12745315
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941

Auteurs

Yohannes Hailemichael (Y)

Department of Reproductive Health and Health Services Management, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. yohannes.h.michael@gmail.com.
Department of Health Economics, Policy and Management, College of Health Sciences, Jimma University, Jimma, Ethiopia. yohannes.h.michael@gmail.com.

Charlotte Hanlon (C)

Department of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Centre for Global Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.
Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Ababa University, Addis Ababa, Ethiopia.

Kebede Tirfessa (K)

Department of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Sumaiyah Docrat (S)

Alan J. Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.

Atalay Alem (A)

Department of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Girmay Medhin (G)

Aklilu-Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.

Abebaw Fekadu (A)

Department of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Department of Global Health & Infection, Brighton and Sussex Medical School, Brighton, UK.
Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Ababa University, Addis Ababa, Ethiopia.
Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.

Crick Lund (C)

Centre for Global Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.
Alan J. Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.

Dan Chisholm (D)

Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland.

Damen Hailemariam (D)

Department of Reproductive Health and Health Services Management, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH